Cellulosic hollow fibre cartridges are used in PK/PD applications when issues with compound binding to polysulfone fibres are detected. One well-known pharmaceutical company put in place the procedure below to check fibre compatability with each new compound prior to PK/PD studies.


If you would like to receive this information as a PDF file please ask: info@kdbio.com

References that cite use of C3008 cellulosic hollow fibre cartridges:

Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model: Bulman, ZP et al.; JAA 52(1) 114-118

High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii: Lenhard, JR et al.; JAC 72(1) 153-165

Azithromycin Pharmacodynamics Against Non-Typeable H. Influenzae: Fisher, J., Yale University Public Health Theses 2016

Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii: Tsuji,BT et al; AAC 2016 60(7)

The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA: Barber,KE et al.; JAC
2015 70(2)

The Hollow Fiber Infection Model for Antimicrobial Pharmacodynamics and
Pharmacokinetics:
Cadwell, J.; Adv Pharmacoepidem Drug Safety 2012

Evaluation of Ceftaroline (CPT) Activity versus Daptomycin (DAP) Against DAP Non-Susceptible Methicillin-Resistant Staphylococcus aureus (MRSA) Strains in an In-Vitro Pharmacokinetic/Pharmacodynamic Model: Steed, M., Ryback, M.; AAC, 2011 55(7)